|

Autologous MUC1-activated T-cells Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Autologous MUC1-activated T-lymphocytes

Pipeline

Phase 1: 1

Top Sponsors

  • Mayo Clinic1

Indications

  • Refractory Primary Peritoneal Carcinoma1
  • Refractory Female Reproductive System Carcinoma1
  • Refractory Fallopian Tube Carcinoma1
  • Recurrent Platinum-Resistant Fallopian Tube Carcinoma1
  • Recurrent Female Reproductive System Carcinoma1

Scottsdale, Arizona1 trial

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Mayo Clinic in Arizona

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.